Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Sanofi has the largest patent position in the field and no disclosed clinical program, which means either an undisclosed asset or a very deliberate royalty strategy
preferential MC1R agonist driving eumelanin synthesis via cAMP/PKA/MITF pathway with enhanced DNA repair signaling
Taste is neutral, packaging arrives protected, and the documentation is refreshingly straightforward
A bridge payment demonstration kicks off in July 2026, with beneficiaries paying just $50/month in copay
Additionally, genetic factors affecting medication metabolism could influence individual response
US$ 27.85
US$ 21.28
US$ 27.96
